Macrosalb (Macrosalb (99mtc))

The active ingredient, Macrosalb, forms a complex with technetium‑99m that selectively binds to target tissues after intravenous injection. The gamma‑emitting radionuclide then highlights physiological activity on a gamma camera, providing visual information about organ function or disease presence.

The specific activity and volume of Macrosalb are determined by the prescribing physician based on the intended imaging study, patient weight, and regulatory guidelines. The prescriber sets the appropriate dose at the time of preparation.

Macrosalb involves exposure to ionizing radiation, which can pose risks to a developing fetus and nursing infant. It should only be used in pregnancy or breastfeeding when the diagnostic benefit outweighs the potential risk, and appropriate precautions are taken.

To order Macrosalb, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Macrosalb offers a ready‑to‑use kit for technetium‑99m labeling, providing flexibility and rapid preparation compared with pre‑filled syringes. Its performance in bone and cardiac imaging is comparable to other 99mTc‑based agents, while its kit format can reduce waste and allow on‑site customization.

Macrosalb should be stored at ambient temperature, protected from light and moisture, and kept in its original sealed container until use. The kit must be prepared under aseptic conditions, and any unused portion should be discarded according to local radiation safety regulations.

Macrosalb is prepared according to the kit instructions, labeled with technetium‑99m, and then administered intravenously by a qualified healthcare professional. The injection is typically performed shortly before the imaging procedure to ensure optimal tracer distribution.

Serious risks include severe allergic reactions (anaphylaxis), significant hypotension, radiation‑induced tissue injury, and organ‑specific toxicity such as renal impairment. Patients should be monitored closely after injection, and emergency measures should be available to manage any adverse events.

Macrosalb should not be used in patients with known hypersensitivity to any kit component, in pregnant or breastfeeding women unless absolutely necessary, and in individuals where the radiation dose poses an unacceptable risk, such as those with severe renal dysfunction without dose adjustment.